Vaccine adjuvants: Why and how

Human Vaccines and Immunotherapeutics

Volumn 12, Issue 10, 2016, Pages 2709-2711

  Christensen, Dennis ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

adjuvant; immunogenicity; immunostimulators; sub unit; vaccine

Indexed keywords

BCG VACCINE; DIPHTHERIA TOXOID; HEPATITIS B SURFACE ANTIGEN; SUBUNIT VACCINE; VACCINE; IMMUNOLOGICAL ADJUVANT;

DRUG DELIVERY SYSTEM; DRUG SAFETY; HAEMOPHILUS INFLUENZAE; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; NONHUMAN; NOTE; PAPILLOMAVIRUS INFECTION; IMMUNOLOGY;

ADJUVANTS, IMMUNOLOGIC; HUMANS; VACCINES;

EID: 84992092119     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2016.1219003     Document Type: Note

References (11)

1. WHO. Polio cases worldwide. www.polioeradication.org. Last accessed June2016
2. WHO and UNICEF (July 2015). Guidance on how to prioritize globally constrained BCG vaccine supply to countries. http://www.who.int/immunization/diseases/tuberculosis/BCG-country-prioritization.pdf?ua=1. Last accessed June2016
3. A.Glenny, C.Pope, H.Waddington, U.Falacce. The antigenic value of toxoid precipitated by potassium alum. J Pathol Bacteriol 1926; 29:31-40; http://dx.doi.org/10.1002/path.1700290106
4. D.T.O'Hagan, G.S.Ott, G.V.Nest, R.Rappuoli, G.D.Giudice. The history of MF59® adjuvant:a phoenix that arose from the ashes. Expert Rev Vaccines 2013; 12(1):13-30; PMID:23256736; http://dx.doi.org/10.1586/erv.12.140
5. R.Glück, I.C.Metcalfe. New technology platforms in the development of vaccines for the future. Vaccine 2002; 20(Suppl 5):B10-6; PMID:12477412; http://dx.doi.org/10.1016/S0264-410X(02)00513-3
6. S.J.Keam, D.M.Harper. Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix]. Drugs 2008; 68(3):359-72; PMID:18257611; http://dx.doi.org/10.2165/00003495-200868030-00007
7. W.T.Walker, S.N.Faust. Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine. Expert Rev Vaccines 2010; 9(12):1385-98; PMID:21105775; http://dx.doi.org/10.1586/erv.10.141
8. RTS Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa:final results of a phase 3, individually randomised, controlled trial. Lancet 2015; 386(9988):31-45; PMID:25913272; http://dx.doi.org/10.1016/S0140-6736(15)60721-8
9. J.T.van Dissel, S.M.Arend, C.Prins, P.Bang, P.N.Tingskov, K.Lingnau, J.Nouta, M.R.Klein, I.Rosenkrands, T.H.Ottenhoff, et al. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers. Vaccine 2010; 28(20):3571-81; PMID:20226890; http://dx.doi.org/10.1016/j.vaccine.2010.02.094
10. J.T.van Dissel, S.A.Joosten, S.T.Hoff, D.Soonawala, C.Prins, D.A.Hokey, D.M.O'Dee, A.Graves, B.Thierry-Carstensen, L.V.Andreasen, et al. A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human. Vaccine 2014; 32(52):7098-107; PMID:25454872; http://dx.doi.org/10.1016/j.vaccine.2014.10.036
11. A.Penn-Nicholson, H.Geldenhuys, W.Burny, R.van der Most, C.L.Day, E.Jongert, P.Moris, M.Hatherill, O.Ofori-Anyinam, W.Hanekom, et al. Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting. Vaccine 2015; 33(32):4025-34; PMID:26072017; http://dx.doi.org/10.1016/j.vaccine.2015.05.088